Can Exosomes Succeed Where Stem Cells Haven’t?

Getting your Trinity Audio player ready...

Stem cells are the ‘magic bullets’ that never really seemed to deliver. Since the early days of stem cell research, scientists have been hopeful that stem cells could lead to revolutionary new regenerative medical treatments. If pluripotent stem cells (cells capable of developing into any cell type) could be introduced into damaged tissue, they would hopefully (perhaps with a bit of coaxing) develop into the necessary cell types to repair even the most severe damage. For example, late stage type II diabetes could be cured by regenerating insulin-producing pancreatic beta cells, and cardiac tissue that died following a heart attack could be replaced. Eventually, entire organs could be generated from a patient’s own stem cells, solving the organ transplantation shortage. While these applications are still possible in principle, and stem cell therapies have found success in some specific diseases, the reality has been somewhat disappointing.

The Reality Check

Stem cells were initially harvested from human embryos, which raised both ethical concerns and supply limitations. Embryonic stem cells could also be rejected by the recipient’s immune system. These issues seemed to be mostly solved when, in 2006, researchers generated the first induced pluripotent stem cells (iPSCs). By exposing regular cells to a cocktail of molecules called Yamanaka factors (or reprogramming factors), autologous pluripotent stem cells (stem cells generated from the patient’s own cells) could be obtained on-demand.

Despite the initial promise, stem cell therapies ran into technical and practical hurdles that still haven’t been overcome. Getting the therapeutic stem cells to behave in the intended manner once administered is one such hurdle. Stem cells might not differentiate into the intended cell type or they may not differentiate at all – the inhospitable environment of the diseased tissue may cause the stem cells to die or self-destruct. If the stem cells do differentiate correctly, they may not organise themselves into functional tissue.

There are also safety risks, the most significant of which is the possibility that stem cells could form cancers when implanted. This risk comes from the nature of stem cells and the reprogramming process. Stem cells divide rapidly, and the reprogramming of normal cells into stem cells can re-activate cancer-causing mutations that were previously suppressed as part of the cell’s natural defence mechanisms against cancer. This means that if a cell used to generate iPSCs had a cancer-causing mutation or acquired one during cell culture, it could lead to the formation of a tumour in the recipient.

Rise of the Stem Cell Clinic

These concerns did not prevent a surge in private clinics offering stem cell therapies for just about anything. Not all of these therapies are completely without scientific foundation. If someone has an incurable, debilitating and fatal disease, it’s understandable that they might want to try an unproven therapy even if the chances of success are slim. The problem is that many private clinics do not properly communicate either the likelihood of success or the level of risk when it comes to their treatments.

Clinical trials carried out in most developed countries are closely watched by regulators, ensuring that informed consent is given and that there are reasonable grounds to think that the treatment’s benefits outweigh the risks. However, in places where regulations are less strict (or for clinics operating ‘under the radar’), there are no such obligations. Implanting stem cells into the brain of a Parkinson’s patient with few years to live, in the hope that they may regenerate their dopaminergic cells based on animal evidence, is one thing. Injecting stem cells into the blood of a child with autism, when there is no consensus on what causes autism or whether the stem cells would have an impact on any hypothetical cause, is something else entirely. Unfortunately, not everyone can tell the difference – especially when some unscrupulous private clinics are working to misrepresent the research to desperate people.

All this has, unsurprisingly, eroded general trust in the idea of stem cell therapy as a whole.

Exosomes: The Next Step?

The idea of repairing otherwise permanent tissue damage with stem cells still isn’t out of the question, but there is a new avenue of research that has been gaining attention. Instead of implanting stem cells themselves into patients, we may be able to replicate many of their effects using the factors that they secrete.

Recently, scientists discovered that many of the tissue repair benefits that come from stem cells are not due to the stem cells dividing and differentiating to form new tissue, but rather due to the release of chemical signals that encourage repair. These chemical signals come in the form of exosomes – nanoscopic particles around the size of a virus that contain proteins, fats and genetic material. Exosomes can be released by one cell and absorbed by another cell, wherein the contents trigger some response. Researchers have found that delivering exosomes isolated from stem cells can, by itself, greatly enhance wound healing, even in wounds that would usually not resolve. While exosomes might not be able to regenerate an entire organ, they could bypass a lot of the challenges that have kept stem cells out of the clinic in many diseases. They can’t form tumours, are less likely to be rejected by the immune system, and are easier to store, handle and produce at scale.

The Current State Of Exosome Research

This review gives an overview of the current state of progress regarding exosome research, specifically for exosomes from stem cells derived from adipose (fat) tissue. Adipose-derived mesenchymal stem cells (ADSCs) have proven to be a particularly efficient source of exosomes because they are easy to harvest from a patient’s adipose tissue and divide quickly in culture. Exosomes from ADSCs have also been found to be better than those from other stem cell types at promoting tissue regeneration in certain contexts. Note that ADSCs aren’t iPSCs that are generated from fully developed fat cells – they are naturally present within the fat tissue, which is why their exosomes have different properties from those of other stem cells. Despite being located within adipose tissue, these cells still have the ability to develop into many cell types including those not found within adipose tissue, such as heart muscle cells.

Summary:

• Animal evidence suggests that ADSC exosomes accelerate wound healing, including in healing-resistant wounds like those found in diabetics. Some early clinical trials reported benefits in diabetic patients.
• Animal evidence suggests that ADSC exosomes enhance both bone and muscle repair, but their applications in humans are mostly unexplored.
• ADSC exosomes appear to help oxygen-deprived heart tissue to recover somewhat in animal models, but no human clinical trials have been conducted.
• Animal evidence suggests that ADSC exosomes promote recovery following nerve injuries and might slow the progression of neurodegenerative diseases, but there’s no human evidence yet.
• There is limited animal evidence that exosomes derived from the blood of young animals reverse some signs of ageing in older animals, but more evidence is needed to make any firm conclusions.

Wound healing: Studies have demonstrated that ADSC-exosomes can activate genes and signalling pathways to promote wound healing. This translates to improved wound healing in animal models – for example, one study encapsulated exosomes within a hydrogel (a jelly-like material that is mostly water). They then applied that hydrogel to skin injuries in mice and found that they healed significantly faster when compared to mice receiving a hydrogel application alone.

The hope is that exosomes could be used to treat wounds that are usually resistant to healing, such as diabetic wounds. High blood sugar in diabetes can damage small blood vessels, leading to reduced oxygen delivery, impairing wound healing. This is a problem for stem cells, as they may struggle to survive in conditions of low oxygen, but exosomes don’t have this problem. Several studies have so far demonstrated that exosomes can promote healing in rats with diabetic wounds. There have been a few early clinical trials reporting benefits in diabetic patients, but we are awaiting larger trials to provide more conclusive evidence.

Regenerating muscle and bone tissue: ADSC-exosomes have been found to have beneficial effects on both muscle and bone repair. These exosomes can enhance the activity of osteoblasts (cells that form new bone) and in animal models, were found to promote bone formation when applied in a hydrogel. ADSC-exosomes injected into injured muscle tissue reduced inflammation, improved blood supply and accelerated healing in animals.

Both of these properties would be highly beneficial for delaying age-related disability, since sarcopenia and osteoporosis together (the loss of muscle mass and bone mass respectively) are the main causes of falls, fractures and the resulting disability among the elderly. Aside from in certain severe muscle wasting diseases, most human exosome treatments for muscle and bone repair are in the early stages of development.

Regenerating heart tissue: Heart tissue has very limited ability to repair itself compared to most other human tissues. If an area of skeletal muscle tissue is damaged, that damage will usually be fully repaired by resident muscle stem cells, with lost tissue replaced by functioning muscle complete with new blood vessels. Yet if cardiac muscle is damaged, it will instead by replaced with scar tissue, never to fully heal. It was once thought that the adult heart had essentially no capacity to repair itself at all, however scientists now know that the heart still possesses its own resident stem cells that slowly self-renew.

Scientists have found that in animal models, blood supply to ischaemic heart tissue (heart tissue that no longer receives adequate blood supply) can be significantly increased by injecting ADSC-exosomes, effectively reducing the area affected following a heart attack. ADSC-exosomes were found to affect the activity of specific genes in order to improve healing in injured heart tissue, such as by inhibiting apoptosis (‘cell suicide’), inhibiting inflammation and promoting blood vessel formation. While these animal findings are promising, there are no ongoing human clinical trials for this application of exosomes in humans.

Regenerating the nervous system: Another type of tissue that struggles to repair itself following injury is nervous tissue. There’s some debate over the extent to which neurons can regenerate after injury, but in practice, when the nervous system is damaged due to disease or injury, it often cannot fully recover or recovers extremely slowly. In the case of incurable neurodegenerative diseases like dementia and multiple sclerosis, there is of course great incentive to find treatments that can prevent or slow down the rate of damage to the nervous system.

Experiments in both cells and live animals suggest that ADSC-exosomes can promote growth and division of neurons and of Schwann cells. Schwann cells produce the protective wrapping known as myelin that surrounds many nerves and accelerates nerve impulses. It is the myelin that is mistakenly targeted by the immune system in multiple sclerosis. In rat models of spinal cord injury, ADSC-exosomes were found to significantly improve recovery. In a mouse model of Alzheimer’s disease, ADSC-exosomes were found to reduce neuronal cell death and inflammation. However, there are no ongoing human clinical trials for the use of exosomes in neurodegenerative conditions or nerve injury.

Slowing the ageing process: A relatively recent and remarkable discovery is that taking plasma (the liquid portion of the blood with all of the blood cells removed) from a young animal and injecting it into an older animal appears to reverse some signs of ageing. Older animals become physically and cognitively fitter after receiving plasma from young animals. There’s some disagreement about how this happens, but it is likely to be a combination of two things: dilution of harmful factors within the blood of old animals, and introduction of new beneficial factors within the plasma of young animals that the old animals no longer produce.

Some research points towards exosomes as the main component of young plasma leading to rejuvenation in old animals. Studies report replicating the benefits of young plasma by injecting just the fraction of the plasma that contains exosomes. However, we are still waiting for some of these studies to be replicated, and there’s not enough evidence to draw firm conclusions about the role of exosomes in ageing just yet.

The Take-Home Message

Exosomes derived from stem cells might be able to replicate many of the promised benefits of stem cell therapy, without as many downsides. They can’t form tumours, won’t die in unfavourable conditions and are less likely to trigger an immune reaction. While promising, exosome research is still in its early phases, and at the time of writing (October 2025) no exosome therapy had been approved for use in humans by either the FDA or the EMA (the US and EU regulatory authorities respectively).

Unfortunately, just as in the case of stem cell therapy, private clinics have been quick to jump on the bandwagon of exosome hype. You can easily find clinics in Europe and the United States offering exosome therapy, asserting that it improves skin health, regenerates hair follicles and slows down the ageing process. These claims are not backed up by scientific evidence, and while exosomes appear to be a lot safer than stem cells, the real world safety evidence is still limited due to the fact that most clinical trials involving exosomes are in their early stages. Exosomes still carry a risk of triggering an immune reaction, and there is a risk of contamination if they are not properly prepared. We also don’t have any scientific data for the long-term effects of regular exosome therapy – we only know that exosome treatments appear to be safe in short clinical trials.

Exosomes aren’t able to do everything that stem cells are in theory capable of, and stem cells will hopefully take a more prominent place in regenerative medicine eventually. While progress has been slow, that doesn’t mean that progress isn’t being made. Our ability to get stem cells to develop not just into the desired cell types, but also to organise themselves in the necessary way (such as getting heart cells to form electrical connections) is increasing. This is partly down to the development of biological ‘scaffolds’ that help stem cells to arrange themselves into functioning tissues. Scientists can now use stem cells to grow ‘organoids’ – miniature, 3D organs made from human cells that can be used to test drugs. While these organoids can’t be transplanted into humans, they are a step towards that goal. In the meantime, we hope that exosomes can deliver some of the long-awaited payoff of stem cell research.